Affordable Access

deepdyve-link
Publisher Website

Chromatin-modifying agents in anti-cancer therapy.

Authors
  • Seidel, Carole1
  • Florean, Cristina
  • Schnekenburger, Michael
  • Dicato, Mario
  • Diederich, Marc
  • 1 Laboratoire de Biologie Moléculaire et Cellulaire de Cancer, Hôpital Kirchberg, 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg. , (Luxembourg)
Type
Published Article
Journal
Biochimie
Publication Date
Nov 01, 2012
Volume
94
Issue
11
Pages
2264–2279
Identifiers
DOI: 10.1016/j.biochi.2012.05.012
PMID: 22627380
Source
Medline
Language
English
License
Unknown

Abstract

Epigenetic alterations are involved in every step of carcinogenesis. The development of chromatin-modifying agents (CMAs) has provided the ability to fight cancer by reversing these alterations. Currently, four CMAs have been approved for cancer treatment; two DNA demethylating agents and two deacetylase inhibitors. A number of promising CMAs are undergoing clinical trials in several cancer types. Moreover, already approved CMAs are still under clinical investigation to improve their efficacy and to extend their use to a broader panel of cancers. Combinatorial treatments with CMAs are already considered a promising strategy to improve clinical benefits and to limit side effects. The real mechanisms by which these CMAs allow the improvement and remission of patients are still obscure. A deeper analysis of the molecular features expressed by responding patients should be performed to reveal this information. In this review, we focus on clinical trials with CMAs, discussing the success and the pitfalls of this new class of anti-cancer drugs. Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times